关于高氏病的概述 高氏病的概述
Daniela Anahí Méndez-Cobián1,2, Sandra Guzmán-Silahua1,3, Diana García-Hernández1,4
1Unidad de Investigación Epidemiológica y en Servicios de Salud, Centro Médico Nacional de Occidente Órgano de Operación Administrativa Desconcentrada Jalisco, Instituto Mexicano del Seguro Social, Guadalajara 44329, Jalisco, Mexico.
Diagnostics (Basel, Switzerland)
|January 8, 2025
概括
墨西哥的高希氏病 (GD) 管理受益于早期诊断和酶替代疗法 (ERT). 需要对神经病变类型和墨西哥GD流行病学进行进一步研究,以改善患者的治疗结果.
科学领域:
- 遗传学和罕见疾病.
- 代谢障碍 代谢障碍 代谢障碍
- 血液学 血液学 血液学
背景情况:
- 氏病 (Gaucher disease,简称GD) 是一种由GBA1基因突变引起的自体逆向性疾病.
- 导致葡萄糖大脑化酶缺乏和葡萄糖大脑化物在巨细胞中的积累.
- 主要影响肝脏,脏和骨髓,专注于墨西哥人口.
研究的目的:
- 审查GD流行病学,临床表现和墨西哥的治疗.
- 提升早期诊断,优化高氏病患者的治疗结果.
- 提供有关在墨西哥背景下的具体挑战和方法的见解.
主要方法:
- 综合文献审查方法.
- 对流行病学数据,临床表现和治疗策略的分析.
- 包括酶替代疗法 (ERT) 和基质减少疗法 (SRT).
主要成果:
- 早期诊断和个性化治疗,特别是ERT,显著改善了Gaucher病1型的预后.
- 目前的治疗方法侧重于治疗症状和酶缺乏症.
- 强调需要人口特异性数据,特别是在墨西哥.
结论:
- 个性化治疗,主要是ERT,对于有利的高氏病预后至关重要.
- 对神经病性GD类型和墨西哥流行病学数据进行进一步的研究是必不可少的.
- 更好的理解和有针对性的疗法将提高患者的生活质量.
相关概念视频
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
Parkinson's Disease: Overview
472
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
472
Cystic Fibrosis: Pathogenesis
185
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
185
Glucose Transporters
22.4K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.4K
Inborn Errors of Metabolism
126
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
126
Alzheimer's Disease: Overview
444
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
444


